Summary We have investigated the relationships between nitrosourea structure and physicochemical properties and the ability of misonidazole (MISO) McNally, 1982; Siemann, 1982) . However, the magnitude of chemopotentiation realized when drugs are combined with MISO is agent-specific, suggesting that certain inherent properties of individual drugs are important in determining the extent of the interaction. Determination of those properties of anti-tumour drugs which favor an interaction with MISO would provide valuable insight into the mechanism(s) of chemopotentiation and could guide the synthesis of improved chemosensitizing agents.
The radiation sensitizer Misonidazole (MISO) has been shown to enhance the cytotoxicity of many conventional chemotherapeutic agents (reviewed by McNally, 1982; Siemann, 1982) . However, the magnitude of chemopotentiation realized when drugs are combined with MISO is agent-specific, suggesting that certain inherent properties of individual drugs are important in determining the extent of the interaction. Determination of those properties of anti-tumour drugs which favor an interaction with MISO would provide valuable insight into the mechanism(s) of chemopotentiation and could guide the synthesis of improved chemosensitizing agents.
In the case of nitrosourea chemotherapy agents, our previous investigations suggest that the extent of enhancement achieved in MISO-nitrosourea combinations in vivo might be correlated with the carbamoylating potential of the nitrosourea used in the combination (Mulcahy, 1982) . However, interpretation of these structure-activity relationships was complicated by possible differences in biodistribution and differential hepatic microsomal metabolism (Reed, 1981; Weinkam & Lin, 1982; Lee & Workman, 1983 
Cell line
EMT-6/Ro tumour cells were routinely grown in BME supplemented with 15% (v/v) foetal and donor calf serum (1:1) and maintained in an atmosphere of 97% air/3% CO2 at 37°C. Exponentially growing EMT-6 cells were trypsinized from monolayers and placed into suspension culture for drug exposure. Survival was determined using a standard plating efficiency assay.
Drugs
The nitrosoureas chosen for these investigations, their structures and relative alkylating and carbamoylating activities are listed in Table I .
All nitrosoureas, with the exception of CHLZ, were initially dissolved in absolute alcohol and diluted 1:100 upon addition to vials containing medium and cells. The final concentration of alcohol (1%) did not significantly influence the plating efficiency relative to controls. CHLZ was dissolved in complete BME.
Drug exposure 1-2 x 106 EMT-6 tumour cells were suspended in 1Oml of BME in type 1 vials as described by Whillans & Rauth (1980) . For exposures under aerobic conditions cells were added to BME in the vials immediately, whereas for hypoxic exposures the cells were added only after the BME had been gassed for 3 h with a 97% N2/3% CO2 gas mixture at a flow rate of 75 ml min-1. Prior to their For experiments in which cells were exposed to MISO and the nitrosoureas simultaneously, MISO was dissolved in complete BME at a concentration of 1.0mM prior to the initiation of any gassing sequence, and was present during the gassing phase.
Results
The relative aerobic and hypoxic cytotoxicities of the various nitrosoureas are displayed in Figure 1 . The majority of the nitrosoureas were equally effective against EMT-6 cells treated under aerobic or hypoxic conditions. However, CHLZ and Bis-OH CyNU, displayed preferential cytotoxicity for hypoxic and aerobic cultures, respectively.
With the exception of CHLZ the addition of 1.0ml MISO to the incubation medium enhanced the cytotoxicity of each of the nitrosoureas under hypoxic conditions. The addition of MISO to Bis-OH CyNU treatment shifted the dose response curve to the left such that the combined treatment was equivalent to aerobic treatment with Bis-OH CyNU alone, effectively eliminating the protection afforded by hypoxia. In all cases the aerobic toxicity of the drugs was not significantly modified by the addition of 1.0mM MISO. Survival following 4h treatment with MISO under hypoxic conditions was 50%. All survival data has been corrected for the cytotoxicity of MISO alone.
When the Dose Effect Factor (DEF; defined as the ratio of nitrosourea concentration required to reduce cell survival to 10 -3 under hypoxic conditions in the absence or presence of 1.0mM MISO) is plotted as a function of the relative carbamoylating activity of the individual nitrosoureas, a significant correlation (P<0.05) between DEF and carbamoylating potential could be demonstrated (Figure 2 ), left hand panel). A similar analysis as a function of alkylating potential failed to establish a significant relationship between enhancement by MISO and alkylation (P> 0.2, Figure 2 right hand panel). Use of DEFs B.J.C.-C determined at other isoeffect levels did not significantly alter the relationships established using the 10 -3 data.
Discussion
The cytotoxicity of the ajiti-neoplastic nitrosoureas toward tumour cells is thought to be mediated through the non-enzymatic generation of reactive daughter products which alkylate DNA, induce DNA strand cross-linking and thereby interrupt cellular reproduction (reviewed by Wheeler, 1976; Kohn et al., 1981) . In addition to alkylating species, the decomposition of the nitrosoureas simultaneously gives rise to relatively non-toxic, but highly reactive (Montgomery et al., 1967) isocyanates which are capable of carbamoylating proteins by interacting with -OH, -SH, and -NH2 residues potentially compromising cellular metabolism, enzyme integrity and repair capacity. Although virtually all nitrosoureas decompose to alkylating and carbamoylating intermediates, their relative alkylating and carbamoylating potential differ significantly. While alkylation has been associated with cytotoxicity and mutagenicity (Wheeler et al., 1974; Bradley et al., 1980) , carbamoylation has been related to DNA repair inhibition (Kann et al., 1980a) and synergism with other DNA damaging agents such as ionizing radiation (Kann et al., 1980b) and conventional alkylating agents (Schabel, 1976) .
Initial in vivo studies evaluating the effectiveness of combining MISO with BCNU (Mulcahy et al., 1981) , CCNU (Siemann, 1981) and CHLZ indicated that the magnitude of the resulting chemopotentiation was nitrosourea dependent, in spite of the drugs structural similarities (Table I) . Since these agents differed significantly with respect to alkylating and carbamoylating properties we investigated the relationship between these chemical properties and each of the nitrosourea's interaction with MISO. These studies, as well as subsequent in vivo investigations, suggested that carbamoylation, rather than alkylation, was directly related to the extent of MISO chemosensitization (Mulcahy, 1982) . Additional support for such a hypothesis was provided by further work in the KHT tumour system indicating that the repair of potentially lethal damage (PLD) occurring after MISO-nitrosourea treatment was likewise inhibited in direct proportion to relative carbamoylating activity.
Although highly suggestive, interpretation of the in vivo results may have been complicated by several factors including differences in drug distribution, hepatic metabolism and lipidsolubility. Furthermore, owing to the inverse Table I. relationship between the alkylating and carbamoylating potential of the nitrosoureas used in these earlier studies, it has been difficult to conclusively determine whether MISO chemopotentiation was related to high carbamoylating activity or low alkylating activity. We chose therefore to further evaluate the structure-activity relationship in vitro in an attempt to reduce or eliminate the influences of some of the complicating factors encountered in vivo. Such studies take advantage of the fact that a broad spectrum of alkylating and carbamoylating activities can be generated non-enzymatically from various nitrosoureas in vitro as well as in vivo. In addition, the in vitro studies were expanded to include nitrosoureas with similar alkylating activities but differing carbamoylating activities, and vice versa, in order to facilitate discrimination between the relative significance of high carbamoylation or low alkylation.
As can be seen in Figure 2 , MISO potentiates the hypoxic activity of the nitrosoureas in proportion to their relative carbamoylating potential; confirming our previous observations with KHT tumours in vivo. An inverse relationship between alkylating activity and chemopotentiation is not supported by the current findings. These studies identify a chemical property linked to MISO-nitrosourea interaction in vitro, making it possible to evaluate currently proposed mechanisms of potentiation in light of this new information.
Pharmacokinetic alteration secondary to MISO inhibition of hepatic microsomal drug metabolism was identified as a possible mechanism in early chemosensitization reports (Tannock, 1980; Mulcahy et al., 1981) , and is considered the major mechanism by many. Such a hypothesis is strongly supported by extensive CCNU pharmacokinetic investigations recently reported by Lee & Workman (1983) . These authors further suggest that pharmacokinetic alterations may provide an alternative explanation to our initial in vivo correlation between carbamoylation and chemopotentiation since carbamoylating potential and partition coefficient, (a property which may determine the extent of hepatic metabolism) were proportional for each of the nitrosoureas included in our 5 drug series. While pharmacokinetic changes are likely to be involved in nitrosourea chemosensitization in vivo to a greater or lesser extent, it is difficult to reconcile all the available chemosensitization data in light of this mechanism alone. Especially difficult to explain on this basis is in vitro data which clearly establish that MISO can enhance drug cytotoxicity without modification of drug decay (Tannock & Guttman, 1982; Mulcahy & Dembs, 1983) . It is unlikely, for example, that the relationship observed in the current in vitro studies is the result of modified nitrosourea decomposition because the decay of BCNU, CCNU and CHLZ in vitro is unaltered by MISO (Tannock Lee & Workman, 1983) . The association between PLD repair inhibition in KHT tumour treated with MISO-nitrosourea combinations and relative carbamoylating potential is likewise difficult to explain on a pharmacokinetic basis, suggesting that the enhancement of nitrosourea cytotoxicity by MISO involves other interactions in addition to any pharmacokinetic alterations.
Considering these later data and the reported repair-inhibiting capacity of carbamoylating nitrosoureas it would seem logical to propose that PLD repair-inhibition is somehow involved in MISO chemosensitization of nitrosourea toxicity. Although evidence exists to support this possibility for nitrosoureas as well as other drugs in vivo (reviewed by McNally, 1982; Siemann, 1982) , this particular phenomenon is unlikely to contribute to the correlation reported here since all attempts to demonstrate PLD repair in EMT-6 cells after nitrosourea treatment in vitro have failed (Twentyman, 1978; Mulcahy, unpublished) .
A plausible alternative explanation for our in vitro results is based on the observed selective inhibitory effect of nitrosoureas on the enzyme glutathione reductase (Babson & Reed, 1978) , and intercellular glutathione (GSH) levels. This inhibition, which is proportional to carbamoylating potential (Babson & Reed, 1978) prevents the recycling of glutathione from its oxidized form (GSSG) back to reduced GSH. The depletion of non-protein sulfhydryls (primarily GSH) associated with MISO treatment under hypoxia has already been identified as an integral part of MISO's cytotoxicity and chemosensitizing ability in vitro (reviewed by Brown, 1982; Roizin-Towle et al., 1982) . According to our hypothesis the chemopotentiation observed in our in vitro studies is linked to thiol depletion by MISO and the additional effects of carbamoylation on glutathione reductase and consequently GSH. The end result would be to augment the GSH depletion associated with the hypoxic reduction of MISO and its metabolites while preventing recycling of GSSG (Mulcahy & Dembs, 1983) . As previously suggested (Mulcahy & Dembs, 1983) , this might also explain why it is possible to sensitize these agents in vitro with doses of MISO (0.25-1.0mM for 4h) considered to be too low to adequately reduce thiols concentrations to levels compatible with chemosensitization. It (Babson & Reed, 1978) . It is therefore premature to exclude the possibility that nitrosoureas showing limited carbamoylating potential in the L-lysine system may have selective-activity against other test compounds in vitro or in vivo. With this reservation in mind we have begun to re-standardize the nitrosoureas employed in our studies for their ability to carbamoylate glutathione reductase in vitro and in vivo. It seems unlikely that this re-standardization will adversely affect the correlation reported here since a similar conclusion is obtained if our DEF values are correlated with the specific carbamoylation of glutathione reductase reported by Babson & Reed (1978) for several of the nitrosoureas used in our investigations.
Based on our experience with the chemosensitization of nitrosoureas, we elected to synthesize novel nitro-compounds possessing a leaving group which would liberate an organic isocyanate; similar to the carbamoylating portion generated by the decomposition of the nitrosoureas. Preliminary evaluation of the first few such agents indicate that the addition of a carbamoylating moiety can produce compounds with enhanced chemosensitizing, radiosensitizing and hypoxic cytotoxicity properties as compared to similar structures devoid of an isocyanate precursor.
In conclusion, these studies have demonstrated a correlation between carbamoylation and chemosensitization of a variety of nitrosoureas by MISO in vitro, in agreement with previous studies in the KHT tumour system. We hypothesize that the mechanism of this in vitro effect is related to alterations in the GSH cycle, perhaps secondary to carbamoylation of key enzymes, notably glutathione reductase. Finally, the information gained has been applied to the synthesis of potentially improved modifiers of chemotherapy and radiation responses.
